Tarsons Products Limited reports 20% revenue growth in Q1 FY27; Margins impacted by expansion costs and input price rises

Tarsons Products Limited reports 20% revenue growth in Q1 FY27; Margins impacted by expansion costs and input price rises​

Tarsons Products Limited has reported a strong quarter for the first quarter of Fiscal Year 2027 (Q1 FY27), achieving significant revenue growth across both standalone and consolidated operations. The company noted that margin performance was affected by elevated raw material costs, driven by supply chain disruptions, alongside expenses associated with the commissioning of new facilities in Amta and Panchla.

The company reported a robust 20.9% year-on-year (YoY) revenue growth for its standalone business, while consolidated operations saw a 20.7% increase in revenue from operations. Key drivers for the domestic segment included improved demand environment and the strength of the distribution network, resulting in a 17% YoY growth in the Domestic Business. The Exports Business showed resilience, with revenues growing by 29% Y-o-Y following previous global geopolitical tensions.

Financial Performance Snapshot (Q1 FY27 vs Q1 FY26)​

The financial results highlight operational challenges related to cost management and expansion investment.

Standalone Business Highlights:

Consolidated Business Highlights:

Management Commentary and Strategic Outlook​

Aryan Sehgal, Promoter and Whole Time Director of Tarsons Products Limited, commented on the performance, attributing the revenue growth to deeper customer penetration and improving underlying demand within the existing portfolio. He noted that while margins were impacted by higher raw material prices due to supply chain disruptions and geopolitical challenges, the company is positioned for future margin recovery.

The management highlighted ongoing investments in capacity expansion and facility upgrades as necessary steps toward sustainable long-term growth. The Amta facility has commenced commercial operations, with revenue from this new capacity beginning from Q4 FY26. Furthermore, the cell culture lines at the Panchla facility are expected to be commissioned towards the end of Q2 FY27.

Tarsons is expanding its product portfolio and manufacturing capabilities across various units, including those in West Bengal. The company maintains a two-pronged sales approach: branded sales targeting emerging markets such as Asia Pacific, Middle East, and South America; and ODM sales to supply products in developed markets like the USA and Europe. Tarsons also recently acquired Nerbe, a Hamburg-based distributor specializing in plastic labware products.

The company's infrastructure includes six vertically integrated manufacturing facilities across various locations, with Jangalpur contributing 47.9% to Manufacturing Revenue Contribution in FY26. The robust domestic sales network supports the transition and expansion into new product segments, such as cell culture consumables at the Panchla facility.

TARSONS Stock Price Movement​

On Monday, shares of Tarsons Products Limited edged higher, closing at ₹313.90 after gaining 0.51% on a positive move. The equity recorded a total traded volume of 241,764 shares during the session.